Amit Kumar Halder, Puja Mishra, Souvik Basak, Debjani Roy, Anurag Das, Sucheta Karmakar, Ritam Mondal, Shrestha Banerjee, Prakarsha De, Ankit Chatterjee, Susmita Mallick, Abhijit Hazra
Six drugs (dapsone, diltiazem, timolol, rosiglitazone, mesalazine, and milnacipran) that were predicted by network-based polypharmacology approaches as potential anti-Alzheimer's drugs, have been subjected in this study for in silico and in vitro evaluation to check their potential against protein fibrillation, which is a causative factor for multiple diseases such as Alzheimer's disease, Parkinson's disease, Huntington disease, cardiac myopathy, type-II diabetes mellitus and many others. Molecular docking and thereafter molecular dynamics (MD) simulations revealed that diltiazem, rosiglitazone, and milnacipran interact with the binding residues such as Asp52, Glu35, Trp62, and Asp101, which lie within the fibrillating region of HEWL...
January 18, 2024: Journal of Biomolecular Structure & Dynamics